Highlights
This prospective multicenter study evaluated a novel reduced-intensity conditioning regimen for HLA-matched related donor hematopoietic stem cell transplantation in adolescents and adults with severe sickle cell disease, including a small subset undergoing second transplantation after prior graft failure.
The regimen combined thymoglobulin, thiotepa, cyclophosphamide, fludarabine, and low-dose total-body irradiation, followed by graft-versus-host disease prophylaxis with post-transplant cyclophosphamide, mycophenolate mofetil, and sirolimus.
Clinical outcomes were striking: estimated 5-year event-free survival was 96%, 2-year overall survival was 100%, and no graft failure occurred. Acute grade III-IV graft-versus-host disease occurred in 4%, with no chronic graft-versus-host disease reported.
The study also demonstrated robust donor chimerism, with median whole blood chimerism of 100% at day +28 and 97% at day +365, supporting the central aim of achieving durable donor engraftment while limiting toxicity.
Background
Sickle cell disease (SCD) remains one of the most severe inherited hemoglobinopathies worldwide. Its clinical burden extends well beyond recurrent pain crises. Progressive organ injury, stroke, acute chest syndrome, pulmonary hypertension, nephropathy, avascular necrosis, transfusion-related complications, and impaired quality of life often accumulate from childhood into adulthood. Even with advances in supportive care, hydroxyurea, chronic transfusion programs, and more recently gene-based therapies, allogeneic hematopoietic stem cell transplantation (HSCT) remains the only widely established curative treatment with long-term real-world follow-up.
For children with an HLA-matched sibling donor, myeloablative HSCT has produced excellent outcomes in experienced centers, with overall survival frequently exceeding 90%. The challenge has been extending curative transplantation safely to older adolescents and adults. In this population, cumulative end-organ damage, alloimmunization, inflammation, iron overload, and transplant-related vulnerability increase procedural risk. Myeloablative conditioning may be too toxic for some patients, but reduced-intensity strategies have historically faced a different problem: mixed chimerism, graft rejection, or secondary graft failure.
This tension between toxicity and engraftment is particularly important in SCD. Unlike malignant disorders, there is no graft-versus-tumor effect to compensate for incomplete engraftment. Durable donor hematopoiesis is essential not only to reverse the sickle phenotype but also to reduce the long-term risk of graft instability. The present study by Alasbali and colleagues addresses that clinical gap by testing a reduced-intensity but apparently highly immunoablative platform designed to improve engraftment while minimizing graft-versus-host disease (GVHD) and regimen-related toxicity.
Study Design
Design and setting
This was a prospective multicenter study conducted across three sites. The investigators recruited 25 patients with severe sickle cell disease undergoing related-donor HSCT. The study is notable for focusing on an underrepresented transplant population: adolescents and adults rather than young children.
Population
The median age was 26.7 years, with an interquartile range of 18.53 to 32.02 years, underscoring that this was a largely young adult cohort. Donor matching was predominantly optimal: 22 of 25 patients (88%) received a fully matched sibling transplant, while 3 of 25 (12%) underwent a one-antigen-mismatched sibling transplant. Importantly, 12% of patients had previously experienced a second graft failure from an earlier HSCT, making this a clinically challenging group and strengthening the relevance of the engraftment results.
Stem cell source
Stem cell source varied, with 11 patients (44%) receiving bone marrow and 14 (56%) receiving peripheral blood stem cells. This is worth noting because peripheral blood grafts can improve engraftment kinetics but may raise concern for higher GVHD risk in some transplant settings. The low GVHD rates observed here suggest that the prophylaxis platform was effective despite substantial peripheral blood use.
Conditioning regimen
The reduced-intensity conditioning regimen consisted of thymoglobulin, thiotepa, cyclophosphamide, fludarabine, and 200 cGy total-body irradiation. Although classified as reduced intensity, this regimen was clearly engineered to provide strong immunosuppression and marrow niche conditioning. Thiotepa is particularly interesting in this context because of its potent cytotoxic and immunosuppressive properties and its use in settings where durable engraftment is a priority.
GVHD prophylaxis
GVHD prophylaxis included post-transplant cyclophosphamide at a total dose of 100 mg/kg, together with mycophenolate mofetil and sirolimus. Post-transplant cyclophosphamide has transformed allogeneic HSCT across multiple donor settings by selectively depleting alloreactive T cells after graft infusion, thereby reducing GVHD while preserving engraftment and immune recovery characteristics.
Endpoints and follow-up
The main clinical aims were to improve donor engraftment, reduce GVHD, and minimize toxicity. Reported outcomes included event-free survival, overall survival, graft failure, donor chimerism, immunosuppression discontinuation, and acute and chronic GVHD. Median follow-up was 42 months, with an interquartile range of 30 to 49 months, allowing meaningful early- to intermediate-term assessment.
Key Findings
Survival outcomes
The headline results are unusually strong for an adolescent and adult SCD transplant cohort. Estimated 5-year event-free survival was 96%, and 2-year overall survival was 100%. These outcomes compare favorably with many prior reduced-intensity adult SCD transplant experiences, in which graft failure or mixed chimerism has often limited event-free survival despite acceptable overall survival.
Because the sample size was modest, survival estimates should be interpreted with caution. Still, in a field where adult transplantation has historically been constrained by trade-offs between safety and durability, these results are clinically compelling.
Engraftment and chimerism
No graft failure was observed. That is arguably the most important finding in the study. Graft failure has been one of the major barriers to reduced-intensity matched related donor transplantation in older patients with SCD. The absence of graft failure in a cohort that included prior transplant failures suggests that the conditioning backbone achieved its principal biologic objective.
Chimerism data reinforce that conclusion. Median whole blood chimerism was 100% at day +28 and 97% at day +365. These values indicate rapid and durable donor hematopoietic dominance rather than marginal mixed chimerism. For SCD, this matters greatly: stable donor engraftment is associated with sustained correction of the sickling phenotype and reduced risk of late graft instability. The authors also note the potential relevance of optimal donor engraftment to lowering the risk of secondary myeloid neoplasms, an issue of growing importance as more patients with inherited disorders receive prolonged cytotoxic and transplant-based therapies.
GVHD outcomes
Despite the use of peripheral blood in more than half the cohort, the regimen achieved very low GVHD rates. The cumulative 1-year incidence of grade III-IV acute GVHD was 4% (n=1), and no chronic GVHD was observed. This finding is clinically important because chronic GVHD can offset the quality-of-life gains of curative transplantation, especially in nonmalignant disease where the therapeutic bar is appropriately high.
The absence of chronic GVHD is especially reassuring for SCD patients, many of whom already carry substantial burdens of chronic pain, organ dysfunction, infertility risk, and psychosocial stress. A curative strategy that avoids exchanging one chronic disease for another is highly desirable.
Immunosuppression discontinuation
Among evaluable participants, 17 of 21 (81%) were off immunosuppression at 1 year after transplantation. This suggests not only low clinically meaningful GVHD but also a post-transplant course compatible with treatment de-escalation and reduced long-term immunosuppression burden. For younger adults, being able to discontinue immunosuppressive therapy relatively early is important for infection risk, reproductive planning, medication adherence, and overall quality of life.
Clinical interpretation of the efficacy signal
Taken together, the study points to a regimen that may solve a central problem in adult SCD transplantation: how to preserve the lower toxicity profile of reduced-intensity conditioning without sacrificing engraftment. The inclusion of thiotepa may have contributed substantially to this balance, while post-transplant cyclophosphamide likely played a major role in suppressing clinically significant alloreactivity.
Safety and Tolerability
The abstract emphasizes minimization of toxicity as a study aim, but the published summary provides limited granular detail on non-GVHD adverse events such as mucositis, infection, veno-occlusive disease, hemorrhagic cystitis, organ toxicity, or intensive care utilization. As a result, conclusions about comparative safety versus other reduced-intensity platforms should remain measured.
Even so, several indirect safety signals are favorable. The 100% 2-year overall survival, absence of graft failure, low severe acute GVHD incidence, no chronic GVHD, and high rate of immunosuppression discontinuation all support good overall regimen tolerability in this cohort. The use of only 200 cGy total-body irradiation also suggests an intentional effort to limit radiation-related toxicity, although fertility and late-effect data will require longer follow-up.
Why This Regimen May Work
The biologic logic of the regimen is coherent. SCD is characterized by chronic inflammation, endothelial activation, repeated transfusion exposure in many patients, and often substantial recipient immune competence. These factors can create a hostile environment for donor graft establishment. A successful platform therefore needs enough immunoablation to overcome host-versus-graft responses while avoiding the organ toxicity of fully myeloablative regimens.
Thiotepa may strengthen this balance by adding potent immunosuppressive and antineoplastic activity without relying on high-dose total-body irradiation. Fludarabine and cyclophosphamide further deepen immune depletion, while thymoglobulin helps reduce host and donor T-cell activity. After graft infusion, post-transplant cyclophosphamide can eliminate proliferating alloreactive T cells, thereby limiting GVHD even when peripheral blood stem cells are used.
In practical terms, the regimen appears to pair strong engraftment support with strong GVHD control. That combination is exactly what adult SCD transplant programs have been seeking.
Expert Commentary
This study enters a rapidly evolving therapeutic landscape. For severe SCD, treatment decisions increasingly involve comparison not only with supportive care and hydroxyurea but also with newer curative or disease-modifying options, including ex vivo gene addition and gene-editing approaches. Yet matched sibling HSCT retains several advantages when a donor is available: long clinical track record, established curative potential, and in many health systems, greater availability than advanced gene therapy.
The main contribution of this report is not merely that transplantation works in SCD; that has long been known. Its importance lies in demonstrating that a modern reduced-intensity platform can deliver near-complete donor engraftment with minimal GVHD in older patients, a group in whom transplant risk-benefit calculations have historically been more complex.
Still, several caveats matter. First, the study enrolled only 25 patients. Second, it was not randomized and did not include a concurrent comparator arm using another reduced-intensity regimen. Third, detailed toxicity reporting is not available in the abstract, limiting a full appraisal of regimen burden. Fourth, donor availability remains a major bottleneck, since only a minority of patients have an HLA-matched sibling donor. Finally, longer follow-up will be needed to define fertility outcomes, endocrine late effects, infection patterns, and durability of organ recovery.
Generalizability is also worth considering. Results from specialized multicenter transplant programs may not automatically translate to lower-volume centers. Expertise in SCD-specific peri-transplant care, transfusion management, organ assessment, and supportive care remains essential.
Current SCD transplant literature supports the idea that donor chimerism thresholds sufficient to reverse disease may be lower than 100%, particularly in the erythroid compartment. However, this study raises an important counterpoint: achieving very high and sustained whole-blood donor chimerism may offer maximal protection against graft instability and potentially reduce later complications tied to incomplete donor dominance. That may be especially relevant in patients with prior graft failure.
Clinical Implications
For clinicians counseling adolescents and adults with severe SCD who have a matched sibling donor, these data strengthen the case for earlier referral to transplant centers. Historically, many adults have reached transplantation only after years of organ damage, repeated hospitalizations, and declining performance status. A regimen with strong engraftment and low chronic GVHD may shift discussions toward intervention before irreversible morbidity accumulates.
The study is also relevant to donor-source selection. The low GVHD rates despite frequent peripheral blood use may expand practical options for centers and families, though broader confirmation is needed before changing standard preferences in nonmalignant transplantation.
In patients with prior graft failure, the findings are especially encouraging. Salvage transplantation in SCD is often approached cautiously because of concern for repeated rejection and cumulative toxicity. The successful inclusion of such patients suggests this platform may have utility beyond first transplant settings.
Limitations
Several limitations should temper interpretation. The cohort was small, which magnifies the impact of each event and makes precision around survival estimates uncertain. The absence of a control group prevents firm conclusions about superiority over established regimens such as alemtuzumab-based nonmyeloablative transplantation or other fludarabine-containing reduced-intensity approaches. Heterogeneity in donor matching and graft source also complicates mechanistic attribution.
Additionally, the abstract does not report confidence intervals, detailed organ-specific toxicities, infection burden, hospitalization metrics, or patient-reported outcomes. Those endpoints are particularly important in nonmalignant disease, where quality of survival matters as much as survival itself.
Conclusion
Alasbali and colleagues report one of the most impressive contemporary matched related donor HSCT experiences in adolescents and adults with severe sickle cell disease. Their thiotepa-containing reduced-intensity conditioning platform, combined with post-transplant cyclophosphamide, produced estimated 5-year event-free survival of 96%, 2-year overall survival of 100%, no graft failure, excellent donor chimerism, very low severe acute GVHD, and no chronic GVHD.
If confirmed in larger cohorts and with longer follow-up, this approach could become an important benchmark for matched sibling transplantation in older SCD patients, including those with prior graft failure. The study’s central message is clinically meaningful: reduced-intensity transplantation does not have to compromise engraftment. In carefully designed regimens, it may be possible to achieve both durability and tolerability, which is precisely the balance adult SCD transplantation has long needed.
Funding and Trial Information
The abstract provided does not specify funding details or a ClinicalTrials.gov registration number. Readers should consult the full Bone Marrow Transplantation article for complete study governance, funding disclosures, and protocol registration information.
References
1. Alasbali R, Alzahrani M, Wilkerson K, Akhom P, Alotaibi F, Alahmari B, de la Fuente J, DeBaun MR, Rasheed W, Samarkandi H, El Fakih R, Saleh M, Elhassan T, Alzahrani H, Aljurf M, Almohareb F, Kassim AA, AlAhmari A. Excellent outcomes using a novel reduced intensity conditioning with thiotepa and post-transplant cyclophosphamide for HLA-matched related donor transplant in adolescents and adults with sickle cell disease. Bone Marrow Transplantation. 2026-04-28. PMID: 42049986.
2. Hsieh MM, Fitzhugh CD, Weitzel RP, et al. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem-cell transplantation for severe sickle cell phenotype. JAMA. 2014;312(1):48-56.
3. Gluckman E, Cappelli B, Bernaudin F, et al. Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. Blood. 2017;129(11):1548-1556.
4. Kanter J, Walters MC, Krishnamurti L, et al. Biologic and clinical efficacy of LentiGlobin for sickle cell disease. N Engl J Med. 2022;386(7):617-628.
5. Frangoul H, Altshuler D, Cappellini MD, et al. CRISPR-Cas9 gene editing for sickle cell disease and beta-thalassemia. N Engl J Med. 2021;384(3):252-260.
6. Arnold SD, Brazauskas R, He N, et al. Clinical practice recommendations on hematopoietic cell transplantation for sickle cell disease: a report from the American Society of Hematology. Blood Adv. 2021;5(18):3668-3689.
